BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khaleel EF, Abdel-aleem GA, Mostafa DG. Resveratrol improves high-fat diet induced fatty liver and insulin resistance by concomitantly inhibiting proteolytic cleavage of sterol regulatory element-binding proteins, free fatty acid oxidation, and intestinal triglyceride absorption. Can J Physiol Pharmacol 2018;96:145-57. [DOI: 10.1139/cjpp-2017-0001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Guo Q, Li F, Duan Y, Wen C, Wang W, Zhang L, Huang R, Yin Y. Oxidative stress, nutritional antioxidants and beyond. Sci China Life Sci 2020;63:866-74. [PMID: 31705360 DOI: 10.1007/s11427-019-9591-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
2 Shazmeen, Haq IU, Rajoka MSR, Asim Shabbir M, Umair M, Llah IU, Manzoor MF, Nemat A, Abid M, Khan MR, Aadil RM. Role of stilbenes against insulin resistance: A review. Food Sci Nutr 2021;9:6389-405. [PMID: 34760269 DOI: 10.1002/fsn3.2553] [Reference Citation Analysis]
3 Cui Y, Wang Q, Chang R, Aboragah A, Loor JJ, Xu C. Network Pharmacology-Based Analysis of Pogostemon cablin (Blanco) Benth Beneficial Effects to Alleviate Nonalcoholic Fatty Liver Disease in Mice. Front Pharmacol 2021;12:789430. [PMID: 34899351 DOI: 10.3389/fphar.2021.789430] [Reference Citation Analysis]
4 Wu L, Guo T, Deng R, Liu L, Yu Y. Apigenin Ameliorates Insulin Resistance and Lipid Accumulation by Endoplasmic Reticulum Stress and SREBP-1c/SREBP-2 Pathway in Palmitate-Induced HepG2 Cells and High-Fat Diet-Fed Mice. J Pharmacol Exp Ther 2021;377:146-56. [PMID: 33509902 DOI: 10.1124/jpet.120.000162] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhao M, Chen S, Ji X, Shen X, You J, Liang X, Yin H, Zhao L. Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease. Pharmacol Res 2021;166:105517. [PMID: 33636349 DOI: 10.1016/j.phrs.2021.105517] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Fan Q, Xu F, Liang B, Zou X. The Anti-Obesity Effect of Traditional Chinese Medicine on Lipid Metabolism. Front Pharmacol 2021;12:696603. [PMID: 34234682 DOI: 10.3389/fphar.2021.696603] [Reference Citation Analysis]
7 Zhou M, Hu N, Liu M, Deng Y, He L, Guo C, Zhao X, Li Y. A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix. Biomed Res Int 2020;2020:5462063. [PMID: 32382557 DOI: 10.1155/2020/5462063] [Reference Citation Analysis]
8 Cheng K, Jia P, Ji S, Song Z, Zhang H, Zhang L, Wang T. Improvement of the hepatic lipid status in intrauterine growth retarded pigs by resveratrol is related to the inhibition of mitochondrial dysfunction, oxidative stress and inflammation. Food Funct 2021;12:278-90. [PMID: 33300526 DOI: 10.1039/d0fo01459a] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Badi RM, Mostafa DG, Khaleel EF, Satti HH. Resveratrol protects against hepatic insulin resistance in a rat's model of non-alcoholic fatty liver disease by down-regulation of GPAT-1 and DGAT2 expression and inhibition of PKC membranous translocation. Clin Exp Pharmacol Physiol 2019;46:545-55. [PMID: 30773673 DOI: 10.1111/1440-1681.13074] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
10 Izzo C, Annunziata M, Melara G, Sciorio R, Dallio M, Masarone M, Federico A, Persico M. The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials. Nutrients 2021;13:933. [PMID: 33805795 DOI: 10.3390/nu13030933] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
11 Perumpail BJ, Li AA, Iqbal U, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A. Potential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD. Diseases 2018;6:E80. [PMID: 30201879 DOI: 10.3390/diseases6030080] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
12 Du H, Li C, Wang Z, He Y, Wang Y, Zhou H, Wan H, Yang J. Effects of Danhong injection on dyslipidemia and cholesterol metabolism in high-fat diets fed rats. J Ethnopharmacol 2021;274:114058. [PMID: 33766756 DOI: 10.1016/j.jep.2021.114058] [Reference Citation Analysis]
13 Haque MR, Ansari SH. Aromatic aldehyde compound cuminaldehyde protects nonalcoholic fatty liver disease in rats feeding high fat diet. Hum Exp Toxicol 2019;38:823-32. [PMID: 30974975 DOI: 10.1177/0960327119842248] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zhou H, Ma C, Wang C, Gong L, Zhang Y, Li Y. Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease. Eur J Pharmacol 2021;898:173976. [PMID: 33639194 DOI: 10.1016/j.ejphar.2021.173976] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Al-otaibi SN, Alshammari GM, Almohanna FH, Al-khalifa AS, Yahya MA. Antihyperlipidemic and hepatic antioxidant effects of Leek leaf methanol extract in high fat diet-fed rats. All Life 2020;13:373-85. [DOI: 10.1080/26895293.2020.1792355] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Wang P, Wang J, Li D, Ke W, Chen F, Hu X. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis. J Nutr Biochem 2020;81:108363. [PMID: 32388250 DOI: 10.1016/j.jnutbio.2020.108363] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
17 Li X, Hu X, Pan T, Dong L, Ding L, Wang Z, Song R, Wang X, Wang N, Zhang Y, Wang J, Yang B. Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway. Biomed Pharmacother 2021;133:110802. [PMID: 33202286 DOI: 10.1016/j.biopha.2020.110802] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
18 Shatoor AS, Al Humayed S, Almohiy HM. Crataegus aronia prevents high-fat diet-induced hepatic steatosis in rats by activating AMPK-induced suppression of SREBP1 and activation of PPARα. J Food Biochem 2021;45:e13945. [PMID: 34585409 DOI: 10.1111/jfbc.13945] [Reference Citation Analysis]
19 Morsy MD, Aboonq MS, ALsleem MA, Abusham AA. Taurine prevents high-fat diet-induced-hepatic steatosis in rats by direct inhibition of hepatic sterol regulatory element-binding proteins and activation of AMPK. Clin Exp Pharmacol Physiol 2020. [PMID: 32691860 DOI: 10.1111/1440-1681.13387] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]